UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2008

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, a non-accelerated filer or a smaller

reporting company. See definitions of "large accelerated filer," "accelerated

filer" and "smaller reporting company" in Rule 12b-2 of the

Exchange Act (Check one):

Large accelerated filer X Accelerated

filer Non-accelerated

filer Smaller

reporting company

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At November 4, 2008, 6,742,935,405 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

September 28, 2008

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months and nine months ended September 28,

2008, and September 30, 2007

Condensed

Consolidated Balance Sheets as of September 28, 2008, and December 31,

2007

Condensed

Consolidated Statements of Cash Flows for the nine months ended September 28,

2008, and September 30, 2007

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

18

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

50

Item 4.

Controls and

Procedures

50

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

51

Item 1A.

Risk Factors

53

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

54

Item 3.

Defaults Upon

Senior Securities

54

Item 4.

Submission of

Matters to a Vote of Security Holders

54

Item 5.

Other

Information

54

Item 6.

Exhibits

54

Signature

55

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(millions,

except per common share data)

Sept.

28,

2008

Sept.

30,

2007

Sept.

28,

2008

Sept.

30,

2007

Revenues

11,973

11,990

35,950

35,548

Costs and expenses:

Cost of sales(a)

2,122

4,618

6,397

8,614

Selling,

informational and administrative expenses(a)

3,523

3,768

10,878

10,973

Research and

development expenses(a)

1,885

1,999

5,642

5,829

Amortization of

intangible assets

621

774

2,063

2,372

Acquisition-related

in-process research and development charges

13

--

567

283

Restructuring

charges and acquisition-related costs

366

455

1,113

2,318

Other

(income)/deductions - net

721

(260)

221

(1,149)

Income from

continuing operations before provision/(benefit) for taxes on income and

minority interests

2,722

636

9,069

6,308

Provision/(benefit)

for taxes on income

463

(161)

1,251

800

Minority

interests

18

Income from

continuing operations

2,253

796

7,800

5,502

Discontinued

operations:

Gain/(loss)

from discontinued operations - net of tax

--

(4)

--

Gains/(losses)

on sales of discontinued operations - net of tax

24

(35)

42

(82)

Discontinued

operations - net of tax

25

(35)

38

(82)

Net income

2,278

761

7,838

5,420

Earnings per common share - basic:

Income from

continuing operations

0.34

0.12

1.16

0.79

Discontinued

operations - net of tax

--

(0.01)

--

(0.01)

Net income

0.34

0.11

1.16

0.78

Earnings per common share -

diluted:

Income from

continuing operations

0.33

0.12

1.16

0.79

Discontinued

operations - net of tax

0.01

(0.01)

--

(0.01)

Net income

0.34

0.11

1.16

0.78

Weighted-average

shares used to calculate earnings per common share:

Basic

6,718

6,875

6,730

6,964

Diluted

6,736

6,894

6,750

6,986

Cash dividends paid per common

share

0.32

0.29

0.96

0.87

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 10B. Goodwill and

Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

Sept. 28,

2008*

Dec. 31,

2007**

ASSETS

Cash and cash equivalents

1,265

3,406

Short-term investments

24,752

22,069

Accounts receivable, less allowance

for doubtful accounts

9,901

9,843

Short-term loans

849

617

Inventories

4,788

5,302

Taxes and other current assets

6,486

5,498

Assets held for sale

186

114

Total current assets

48,227

46,849

Long-term

investments and loans

8,430

4,856

Property, plant and equipment, less

accumulated depreciation

14,332

15,734

Goodwill

21,353

21,382

Identifiable

intangible assets, less accumulated amortization

18,978

20,498

Other assets,

deferred taxes and deferred charges

3,929

5,949

Total assets

115,249

115,268

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

9,193

5,825

Accounts payable

1,649

2,270

Dividends payable

2,163

Income taxes payable

735

1,380

Accrued compensation and related

items

1,752

1,974

Other current liabilities

8,173

8,223

Total current liabilities

21,503

21,835

Long-term debt

7,152

7,314

Pension benefit

obligations

2,425

2,599

Postretirement

benefit obligations

1,747

1,708

Deferred taxes

5,824

7,696

Other taxes

payable

6,594

6,246

Other

noncurrent liabilities

2,513

2,746

Total liabilities

47,758

50,144

Minority interests

156

114

Preferred stock

76

93

Common stock

443

442

Additional

paid-in capital

70,162

69,913

Employee

benefit trust, at fair value

(432)

(550)

Treasury stock

(57,389)

(56,847)

Retained

earnings

53,175

49,660

Accumulated

other comprehensive income

1,300

2,299

Total shareholders' equity

67,335

65,010

Total liabilities and shareholders'

equity

115,249

115,268

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine

Months Ended

(millions

of dollars)

Sept. 28,

2008

Sept. 30,

2007

Operating

Activities:

Net income

7,838

5,420

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

3,912

4,084

Share-based

compensation expense

263

335

Acquisition-related

in-process research and development charges

567

283

Intangible

asset impairments and other associated non-cash charges

--

2,220

Deferred taxes

from continuing operations

580

(1,969)

Other non-cash

adjustments

649

393

Changes in

assets and liabilities (net of businesses acquired and divested)

(1,544)

(1,180)

Net cash provided by operating

activities

12,265

9,586

Investing Activities:

Purchases of

property, plant and equipment

(1,312)

(1,218)

Purchases of

short-term investments

(22,369)

(16,606)

Proceeds from

sales and redemptions of short-term investments

20,642

23,426

Purchases of

long-term investments

(5,292)

(1,406)

Proceeds from

sales and redemptions of long-term investments

639

173

Purchases of

other assets

(36)

(93)

Acquisitions,

net of cash acquired

(962)

(464)

Other investing

activities

(1,365)

(218)

Net cash (used in)/provided by

investing activities

(10,055)

3,594

Financing Activities:

Increase in

short-term borrowings, net

31,035

130

Principal

payments on short-term borrowings

(28,518)

(744)

Proceeds from

issuances of long-term debt

605

1,243

Principal

payments on long-term debt

(561)

(61)

Purchases of

common stock

(500)

(7,494)

Cash dividends

paid

(6,409)

(6,021)

Stock option

transactions and other

41

537

Net cash used

in financing activities

(4,307)

(12,410)

Effect of

exchange-rate changes on cash and cash equivalents

(44)

14

Net

(decrease)/increase in cash and cash equivalents

(2,141)

784

Cash and cash

equivalents at beginning of period

3,406

1,827

Cash and cash

equivalents at end of period

1,265

2,611

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

1,707

4,207

Interest

541

465

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and

operating results for subsidiaries operating outside the U.S. are as of and for

the three-month and nine-month periods ended August 24, 2008, and August 26,

2007.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2007.

Note 2. Adoption of

New Accounting Policies

As of September 28, 2008, we adopted Financial Accounting Standards Board

(FASB) Financial Staff Position (FSP) No. 157-3, Determining the Fair Value

of a Financial Asset When the Market for That Asset is Not Active. This FSP

clarifies Statement of Financial Accounting Standards (SFAS) No. 157 and

provides an example of determining fair value when the market for a financial

asset is not active. The adoption of FASB FSP No. 157-3 did not have a significant

impact on our consolidated financial statements.

As of January 1, 2008, we adopted on

a prospective basis certain required provisions of SFAS No. 157, Fair Value

Measurements, as amended by FASB FSP No. 157-2, Effective Date of

FASB Statement No. 157. Those provisions relate to our financial assets and

liabilities carried at fair value and our fair value disclosures related to financial

assets and liabilities. SFAS 157 defines fair value, expands related disclosure

requirements and specifies a hierarchy of valuation techniques based on the

nature of the inputs used to develop the fair value measures. Fair value is defined

as the price that would be received to sell an asset or paid to transfer a

liability in an orderly transaction between market participants at the measurement

date. There are three levels of inputs to fair value measurements - Level 1,

meaning the use of quoted prices for identical instruments in active markets;

Level 2, meaning the use of quoted prices for similar instruments in active

markets or quoted prices for identical or similar instruments in markets that

are not active or are directly or indirectly observable; and Level 3, meaning the

use of unobservable inputs. Observable market data should be used when

available.

Many, but not all, of our financial

instruments are carried at fair value. For example,

substantially all of our cash equivalents, short-term investments and long-term

investments are classified as available-for-sale securities and are carried at

fair value, with unrealized gains and losses, net of tax, reported in Other

comprehensive income. Derivative financial instruments are carried

at fair value, with changes in fair value reported in various balance sheet

categories (see both Note 10 D. Financial Instruments: Derivative Financial

Instruments and Hedging Activities in our Annual Report on Form 10-K for

the year ended December 31, 2007, and Note 8C. Financial Instruments:

Derivative Financial Instruments and Hedging Activities in this Quarterly

Report) and ultimately, in Other (income)/deductions - net. Virtually

all of our valuation measurements are Level 2 measurements. The adoption of

SFAS 157 did not have a significant impact on our consolidated financial

statements. We did not elect to adopt SFAS 157 for acquired nonfinancial assets

and assumed nonfinancial liabilities.

Emerging Issues Task Force (EITF)

Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or

Services to Be Used in Future Research and Development Activities, became

effective for new contracts entered into on or after January 1, 2008. EITF

Issue No. 07-3 requires that non-refundable advance payments for goods and

services that will be used in future research and development (R&D)

activities be expensed when the R&D activity has been performed or

when the R&D goods have been received rather than when the payment is made.

The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated

financial statements.

Note 3. Acquisitions

During the first nine months of 2008

and 2007, we acquired the following:

In the second quarter of 2008, we

acquired Encysive Pharmaceuticals Inc. (Encysive), a biopharmaceutical

company, whose main product (Thelin), for the treatment of pulmonary arterial

hypertension, is commercially available in much of the E.U., is approved in

certain other markets, and is under review by the Food and Drug

Administration (FDA). The cost of acquiring Encysive, through a tender offer

and subsequent merger, was approximately $200 million, including

transaction costs. Upon our acquisition of Encysive, Encysive's change of

control repurchase obligations under its $130 million, 2.5% convertible

notes came into effect and, as such, Encysive repurchased the convertible

notes in consideration for their par value plus accrued interest in June 2008.

In addition, in the second quarter of 2008, we acquired Serenex, Inc.

(Serenex), a privately held biotechnology company with SNX-5422, an oral Heat

Shock Protein 90 (Hsp90) inhibitor currently in Phase I trials for the potential

treatment of solid tumors and hematological malignancies, and an extensive

Hsp90 inhibitor compound library, which has potential uses in treating cancer

and inflammatory and neurodegenerative diseases. In connection with these

acquisitions, in the first nine months of 2008, we recorded approximately $170

million in Acquisition-related in-process research and development charges

and approximately $450 million in intangible assets.

In the first quarter of 2008, we

acquired CovX, a privately held biotherapeutics company specializing in

preclinical oncology and metabolic research and the developer of a

biotherapeutics technology platform that we expect will enhance our biologic

portfolio. Also in the first quarter of 2008, we acquired all the outstanding

shares of Coley Pharmaceutical Group, Inc., (Coley), a biopharmaceutical

company specializing in vaccines and drug candidates designed to fight

cancers, allergy and asthma disorders, and autoimmune diseases, for

approximately $230 million. In connection with these and two smaller

acquisitions related to Animal Health, in the first nine months of 2008, we

recorded $398 million in Acquisition-related in-process research and

development charges.

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a novel technology platform for developing new protein drug

candidates, and Embrex, Inc., an animal health company that possesses a

unique vaccine delivery system known as Inovoject that improves consistency

and reliability by inoculating chicks while they are still inside the egg. In

connection with these and other small acquisitions, we recorded

$283 million in Acquisition-related in-process research and

development charges.

Note 4. Certain

Charges

A. Product Litigation -

Celebrex and Bextra

In the third quarter of 2008, we

reached agreements in principle to resolve the pending U.S. consumer fraud

purported class action cases and more than 90% of the known U.S. personal injury

claims involving Celebrex and Bextra, and we reached agreements to resolve

substantially all of the cases and claims of state attorneys general involving

Celebrex and Bextra. In connection with these actions, we have recorded charges

of approximately:

$745 million applicable

to all known U.S. personal injury claims;

$89 million applicable

to the pending U.S. consumer fraud purported class action cases; and

$60 million applicable

to agreements to resolve civil cases and claims brought by 33 states and the

District of Columbia, primarily relating to alleged Bextra promotional

practices. Under these agreements, we will make a payment to the states and

adopt compliance measures that complement policies and procedures previously

established by us.

In connection with these actions, we

recorded total litigation-related charges of approximately $900 million in Other

(income)/deductions - net in the third quarter of 2008. Virtually all of

this amount is included in Other current liabilities on the condensed consolidated

balance sheet as of September 28, 2008. Although we believe that we have

insurance coverage for a portion of the proposed personal injury settlements,

no insurance recoveries have been recorded.

We believe that the charges of approximately

$745 million will be sufficient to resolve all known U.S. personal injury

claims, including those not being settled at this time. However, additional

charges may have to be taken in the future in connection with certain pending claims

and unknown claims relating to Celebrex and Bextra.

B. Adjustment of Prior Years'

Liabilities for Product Returns

Revenues in the third quarter of 2008

include a reduction of $217 million to adjust our prior years' liabilities for

product returns. After a recent detailed review of our returns experience, we

determined that our previous methodology needed to be revised, as the lag time

between product sale and return was actually longer than we had previously

assumed. Although fully recorded in the current period, virtually all of the

adjustment relates back several years.

Since this is the correction of an

error, we performed an evaluation of the impact of this error on prior periods,

as well the impact of correcting the error on a cumulative basis in the current

quarter. As a result of that analysis, we determined that the correction of

the error in prior periods would not have been material to any individual

period and we determined that the cumulative correction was not material to our

projected results for fiscal 2008. As such, the cumulative correction was

recorded in the third quarter of 2008. We have also reviewed our expense

calculations for the prior years and determined that the expense recorded in

those years was not materially different from what would have been recorded

under our revised approach.

C. Exubera

In the third quarter of 2007, we

exited Exubera, an inhalable form of insulin for the treatment of diabetes.

Total pre-tax charges for the third quarter and first nine months of 2007 were

$2.8 billion and were included primarily in Cost of sales ($2.6

billion), Selling, informational and administrative expenses ($83

million), and Research and development expenses ($131 million). The

charges were comprised of asset write-offs of $2.2 billion (intangibles,

inventory and fixed assets) and other exit costs, primarily severance, contract

and other termination costs. As of September 28, 2008, the remaining accrual

for other exit costs is approximately $220 million. Substantially all of this cash

spending is expected to be completed in 2009.

Note 5. Cost-Reduction

Initiatives

The costs incurred in connection with

our cost-reduction initiatives, which began in early 2005, follow:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept. 28,

2008

Sept. 30,

2007

Sept. 28,

2008

Sept. 30,

2007

Implementation

costs(a)

378

373

1,140